论文部分内容阅读
目的观察厄贝沙坦联合硝苯地平控释片治疗原发性高血压的临床疗效及安全性。方法选取中心2013年5月——2014年4月门诊收治的92例原发性高血压患者,随机分为治疗组和对照组,治疗组47例给予厄贝沙坦片0.15g+硝苯地平控释片30 mg晨服,1次/d,对照组45例给予厄贝沙坦片0.15g晨服,1次/d,两组用药均为8周,治疗结束后比较两组治疗前后的临床疗效﹑血压﹑心率变化及不良反应。计量资料采用t检验,计数资料采用χ2检验,P<0.05为差异有统计学意义。结果治疗8周后治疗组总有效率为93.62%,对照组为73.33%,治疗组明显高于对照组,两组比较差异有统计学意义(P<0.05)。治疗组治疗后收缩压与舒张压分别为[(123.9±7.3)﹑(74.7±5.8)mm Hg](1 mm Hg=0.133KPa)均显著低于治疗前[(161.7±9.6)﹑(102.5±7.9)mm Hg],对照组治疗后收缩压与舒张压[(136.5±6.8)、(87.5±6.1)mm Hg]明显低于治疗前[(160.8±9.2)﹑(101.8±7.3)mm Hg],比较差异均有统计学意义(P<0.05)。治疗后治疗组收缩压与舒张压[(123.9±7.3)﹑(74.7±5.8)mmHg]显著低于对照组治疗后[(136.5±6.8)mm Hg﹑(87.5±6.1)mm Hg],比较差异均有统计学意义(P<0.05)。治疗组与对照组治疗后心率与治疗前比较,差异均无统计学意义(P﹥0.05),所有患者未发生严重的不良发应。结论厄贝沙坦联合硝苯地平控释片治疗原发性高血压疗效优于单用厄贝沙坦,且作用持久,耐受性﹑安全性较好,适合临床推广使用。
Objective To observe the clinical efficacy and safety of irbesartan and nifedipine GITS in the treatment of essential hypertension. METHODS: A total of 92 patients with essential hypertension admitted to the clinic from May 2013 to April 2014 were randomly divided into treatment group and control group. In the treatment group, 47 patients were given irbesartan 0.15g plus nifedipine The tablets were given for 30 minutes in the morning and once daily for 45 days. The control group was treated with 0.15 g of irbesartan in the morning, once a day for 8 weeks. After the treatment, the clinical scores of the two groups were compared Efficacy, blood pressure, heart rate changes and adverse reactions. Measurement data using t test, count data using χ2 test, P <0.05 for the difference was statistically significant. Results After 8 weeks of treatment, the total effective rate was 93.62% in the treatment group and 73.33% in the control group, which was significantly higher in the treatment group than in the control group. There was significant difference between the two groups (P <0.05). The systolic blood pressure and diastolic blood pressure in the treatment group after treatment were significantly lower than those before treatment [(123.9 ± 7.3) ﹑ (74.7 ± 5.8) mm Hg] (1 mm Hg = 0.133KPa) [(161.7 ± 9.6) ﹑ (102.5 ± 7.96 mmHg]. The systolic and diastolic blood pressure in the control group [(136.5 ± 6.8), (87.5 ± 6.1) mm Hg] were significantly lower than those before treatment [(160.8 ± 9.2), (101.8 ± 7.3) mm Hg] , The difference was statistically significant (P <0.05). The systolic blood pressure and diastolic blood pressure in the treatment group were significantly lower than those in the control group [(123.9 ± 7.3) and (74.7 ± 5.8) mmHg, respectively, compared with those in the control group [(136.5 ± 6.8) mmHg and (87.5 ± 6.1) mmHg) All were statistically significant (P <0.05). There was no significant difference between the treatment group and the control group after treatment (P> 0.05), and no serious adverse reactions occurred in all the patients. Conclusion Irbesartan combined with nifedipine GITS in the treatment of essential hypertension is superior to irbesartan alone, with long-lasting effects, good tolerability and safety, and is suitable for clinical use.